Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Exicure Q3 2026 Results: Turns Profitable, Net Income $642K

Exicure, Inc. reported a net loss of $2.3 million for the nine months ended September 30, 2026, compared to a $2.0 million loss in the prior year period. The company currently generates no revenue and is exploring strategic alternatives while facing substantial doubt about its ability to continue as a going concern.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Profit before tax0.6-2.4
Net income0.6-2.4
EPS (diluted, $ a share)$0.10$-0.39

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: XCUR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Exicure, Inc.: key numbers

Share price
$1.08Close, Nov 17
Market cap
$6.55M
Shares outstanding
6.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Exicure, Inc.

All →
1:01 PM ET 8-K
Partnership

Exicure Partnership with NeuroQ Biologics Inc. and Laonz Co., Ltd. Worth $500K

Exicure entered into a Strategic Business Expansion and Investment Agreement to acquire a 20% to 100% equity stake in NeuroQ Biologics through a share exchange with Laonz Co. The partnership focuses on commercializing X-CUE, an augmented-reality smart-glasses technology for Parkinson's disease patients, with Exicure committing up to $0.5 million in development funding.

Value
$500K
Counterparty
NeuroQ Biologics Inc. and Laonz Co., Ltd.
3:50 PM ET 8-K
Divestiture

Exicure Divestiture to GPCRT Inc. for $4.8M

Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.

Value
$4.8M
Counterparty
GPCRT Inc.
10:27 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Exicure Nasdaq/NYSE Compliance Notice

Exicure, Inc. received an extension from Nasdaq until December 2, 2026, to regain compliance with the minimum $2.5 million stockholders' equity requirement. The company originally received a deficiency notice on June 5, 2026, and must now complete compliance initiatives to avoid potential delisting. This extension provides the company additional time to strengthen its financial position and meet continued listing standards.

Counterparty
Nasdaq
Term
through Dec 2, 2026

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.